Related Experiment Video
Updated: May 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Antioxidant Therapy Reverses Hepatotoxicity Induced by Microcystin-LR in a Cellular Model of Metabolic
Apurva Lad1, Jason Kindle1, Prajwal Hegde1
1Department of Medicine, University of Toledo, Toledo, OH 43614, USA.
Abstract:
Microcystin-LR (MC-LR) is a potent hepatotoxin that has been shown to cause liver damage even at doses lower than the established Low Observable Adverse Effect Level (LOAEL) of 200 μg/kg in animal models. We have previously observed that low-dose exposure to MC-LR in animals with diet-induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and subsequent treatment with antioxidants like N-acetylcysteine (NAC) and the Na+/K+ ATPase-Src kinase inhibitor pNaKtide significantly alleviated hepatic infiltration of immune cells, downregulated markers of inflammation and hepatotoxicity, increased the breakdown of the toxin molecule, and restored phase I and II drug metabolism pathways, including the glutathione pathway. Because the liver is composed of heterogeneous cell types, this study aimed to determine the specific role of hepatocytes in the uptake and metabolism of MC-LR, especially in the setting of MASLD. To address this, we used two well-established hepatocyte cell lines-AML-12 murine hepatocytes and human Hep3B hepatocytes. Preliminary dose comparison studies with AML-12 cells showed that MC-LR at 10 μM concentration showed a significant upregulation in the genetic expression of the markers of hepatotoxicity-OSMR (p ≤ 0.01) and SerpinE (p ≤ 0.0001)-in comparison to Vehicle. Treatment with pNaKtide (1 µM) and/or NAC (10 mM) in the presence of MC-LR significantly reduced the expression of both OSMR (p ≤ 0.0001) and SerpinE (p ≤ 0.01 and p ≤ 0.0001, respectively). To model steatotic hepatocytes characteristic of the MASLD phenotype, Hep3B hepatocytes were first treated with 500 µM of oleic acid (OA) before exposing them to the toxin in the presence and absence of antioxidants. MC-LR exposure, induced markers of inflammation and hepatotoxicity to be elevated significantly in the presence of OA as compared to MC-LR exposure alone. This elevation of the genetic markers of inflammation and hepatotoxicity was significantly attenuated on treatment with pNaKtide (1 µM) and NAC (10 mM). Quantification of human SERPINE1 (PAI1) and 8-OHdG, a stable marker of oxidative stress, in the spent media of Hep3B cells corroborated the trends observed in the genetic markers of hepatotoxicity. These observations support the central role that hepatocytes play in the uptake and metabolism of MC-LR, which is complicated by the presence of MASLD-like conditions and can help in the development of future therapeutic strategies.
Insights
Hepatocytes play a key role in microcystin-LR (MC-LR) liver damage, especially in metabolic dysfunction-associated steatotic liver disease (MASLD). Antioxidants like NAC and pNaKtide can mitigate MC-LR toxicity in hepatocytes.
Area of Science:
- Hepatology
- Toxicology
- Cell Biology
Background:
- Microcystin-LR (MC-LR) is a potent hepatotoxin causing liver damage.
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) complicates MC-LR toxicity.
- Hepatocytes are crucial for toxin metabolism but their specific role in MASLD is unclear.
Purpose of the Study:
- To investigate the specific role of hepatocytes in MC-LR uptake and metabolism.
- To determine how MASLD conditions affect hepatocyte response to MC-LR.
- To evaluate the therapeutic potential of antioxidants in mitigating MC-LR hepatotoxicity in MASLD.
Main Methods:
- Utilized AML-12 murine and Hep3B human hepatocyte cell lines.
- Exposed cells to MC-LR at varying concentrations.
- Modeled MASLD using oleic acid treatment in Hep3B cells.
- Administered N-acetylcysteine (NAC) and pNaKtide as antioxidant treatments.
Main Results:
- MC-LR upregulated hepatotoxicity markers (OSMR, SerpinE) in AML-12 cells.
- NAC and pNaKtide significantly reduced MC-LR-induced marker expression.
- MASLD conditions exacerbated MC-LR-induced inflammation and hepatotoxicity in Hep3B cells.
- Antioxidant treatment attenuated these markers in MASLD-modeled hepatocytes.
- Oxidative stress marker 8-OHdG levels corroborated findings.
Conclusions:
- Hepatocytes are central to MC-LR uptake and metabolism.
- MASLD conditions worsen MC-LR hepatotoxicity.
- NAC and pNaKtide show promise in treating MC-LR toxicity in MASLD.
- Findings support the development of targeted therapeutic strategies.
